Abstract: The invention relates to a new and useful antibiotic substance which is of the formula ##STR1## and to processes for its production and recovery. The antibiotic which exhibits ionophoric properties, is classified as a polyether group antibiotic. the antibiotic of formula I is effective in inhibiting the growth of gram positive bacteria and exhibits utility as an antihypertensive agent and as a compound to improve ruminant feed utilization. The antibiotic of Formula I is prepared by cultivating a strain of Streptomyces sp. X-14547 in an aqueous carbohydrate solution containing nitrogenous nutrients and mineral salts and thereafter isolating the antibiotic from the fermentation broth.
Abstract: Antibiotic A-38533 complex, comprising microbiologically active, related factors A.sub.1, A.sub.2, B and C, is produced by submerged, aerobic fermentation of a new Streptomyces sp., NRRL 11298. The A-38533 antibiotics are closely related antibiotics. The individual A-38533 factors are separated by chromatography. The A-38533 factors are antibacterial agents which have a unique activity against Pseudomonas species.
Type:
Grant
Filed:
May 25, 1978
Date of Patent:
December 25, 1979
Assignee:
Eli Lilly and Company
Inventors:
Otis W. Godfrey, Ronald D. Johnson, Ralph E. Kastner
Abstract: The antibacterial compound S551-II (Reductiomycin) is produced by culturing a microorganism belonging to the genus Streptomyces.S551-II-A is prepared by sublimation of the compound S551-II.
Abstract: Novel microbial transformation process to selectively convert steroids with or without 17-alkyl side chains of from 2 to 10 carbon atoms, inclusive, to 3a.alpha.-H-4.alpha.-[3'-propanol]-7a.beta.-methylhexahydro-1,5-indaned ione hemiketal having the following structure: ##STR1## This compound can be used as an intermediate to make useful 19-nor steroids.
Abstract: Novel aminoglycoside-aminocyclitol derivatives corresponding to the general formula: ##STR1## wherein R.sub.1 and R.sub.2, which are different, represent hydrogen or CH.sub.2 NH.sub.2 and R is selected from the group consisting of: ##STR2## wherein R.sub.3 represents NH.sub.2 or OH and R.sub.4 represents ##STR3## wherein R.sub.5 represents hydrogen or methyl and the pharmaceutically acceptable acid addition salts thereof.They are useful as antibiotics.
Type:
Grant
Filed:
April 13, 1977
Date of Patent:
October 9, 1979
Assignee:
Labaz
Inventors:
Stephan Gero, Daniel Mercier, Alain Olesker, Andre Cier
Abstract: Novel antibiotic CC-1065 producible in a fermentation under controlled conditions using the new microorganism Streptomyces zelensis, NRRL 11,183. This antibiotic is active against Gram-positive bacteria, for example, Staphylococcus aureus, Bacillus subtilis, Streptococcus pyogenes, Sarcina lutea, and Streptococcus faecalis. It is also active against Gram-negative bacteria, for example, Escherichia coli, Proteus vulgaris, Pseudomonas aeruginosa, Klebsiella pneumoniae, and Salmonella pullorum. Thus, antibiotic CC-1065 can be used in various environments to eradicate or control such bacteria.
Abstract: The present invention relates to new physiologically active peptides, derivatives thereof and a process for preparation thereof. In particular, it relates to new tetrapeptides designated amastatins A.sub.1, A.sub.2, A.sub.3, B.sub.1 and B.sub.2 and derivatives thereof which have an inhibitory effect on aminopeptidase A and also show stimulation of antibody formation and to a process for preparation thereof by cultivating a strain belonging to the genus Streptomyces.
Type:
Grant
Filed:
June 16, 1978
Date of Patent:
September 11, 1979
Assignee:
Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai
Inventors:
Hamao Umezawa, Takaaki Aoyagi, Tomio Takeuchi, Masa Hamada
Abstract: The antibiotic N-acetyl thienamycin and its non-toxic pharmaceutically acceptable salts are active against both gram-positive and gram-negative bacteria. The antibiotic is produced by growing a species of Streptomyces on suitable fermentation media or alternatively by acetylation of thienamycin.
Type:
Grant
Filed:
August 25, 1977
Date of Patent:
August 21, 1979
Assignee:
Merck & Co., Inc.
Inventors:
Jean S. Kahan, Frederick M. Kahan, Robert T. Goegelman, Edward O. Stapley, Sebastian Hernandez
Abstract: Novel 18.xi.-, 19.xi.- and 20.xi.-hydroxy-prostaglandin derivatives of the formula I ##STR1## wherein the dotted line in the position 8-12 indicates the optional presence of a double bond, the waved lines in position 15 indicate that the hydroxyl group and the group R.sub.4 are either in .alpha.- or .beta.-position and Z represents a --CH.sub.2 CH.sub.2 -- or a cis --CH.dbd.CH--group, and wherein R represents one of the groups: ##STR2## (wherein the waved lines indicate that the hydroxyl groups are either in .alpha.- or .beta.-position and R.sub.1 represents a hydrogen atom, a methyl or ehtyl group), R.sub.2 represents either an oxygen atom or a hydrogen atom and an .alpha.- or .beta.-hydroxyl group, R.sub.3 represents a hydrogen atom or a hydroxyl group and R.sub.4 represents a hydrogen atom or a methyl group, with the proviso that when simultaneously, R.sub.1, R.sub.3 and R.sub.4 each represents a hydrogen atom, R.sub.
Abstract: The antibiotics MSD 890A.sub.1 and MSD 890A.sub.3 and pharmaceutically acceptable salts thereof (hereinafter referred to as antibiotics 890A.sub.1 and 890A.sub.3) are active against both gram-positive and gram-negative bacteria. The antibiotics are produced by growing species of Streptomyces on suitable fermentation media.
Type:
Grant
Filed:
August 25, 1977
Date of Patent:
July 24, 1979
Assignee:
Merck & Co., Inc.
Inventors:
Patrick J. Cassidy, Robert T. Goegelman, Edward O. Stapley, Sebastian Hernandez
Abstract: This case relates to a novel process which aids in the isolation and purification of novel compounds which are produced by the microorganism, Streptomyces avermitilis. The process described utilizes a non-aqueous extraction system for purifying crude extracts of the novel compounds. The compounds which are isolated and purified are described generically as C-076 and have significant parasiticidal activity.
Abstract: This case relates to a novel process which aids in the isolation and purification of novel compounds which are produced by the microorganism, Streptomyces avermitilis. The process described herein utilizes a high pressure liquid chromatographic system (HPLC) for the isolation and purification of the active compound. The compounds which are isolated and purified are described generically as C-076 and have significant parasiticidal activity.
Abstract: This case relates to a novel process which aids in the isolation and purification of novel compounds which are produced by the microorganism, Streptomyces avermitilis. The process described utilizes a column containing a hydroxyalkylated dextran gel as a step in the separation of the desired compounds. The compounds which are isolated and purified are described generically as C-076 and have significant parasiticidal activity.
Type:
Grant
Filed:
October 11, 1977
Date of Patent:
July 3, 1979
Assignee:
Merck & Co., Inc.
Inventors:
Thomas W. Miller, Kenneth E. Wilson, Robert E. Ormond
Abstract: New antibiotics SF-1130-x.sub.1 substance and SF-1130-x.sub.2 substance are produced by cultivating a microorganism Streptomyces myxogenes SF-1130 now deposited under FERM-P. 676 and ATCC. 31305 in a liquid culture medium under aerobic conditions, and these antibiotics may be isolated from the fermentation broth and are useful as an activator for enhancing the host defense system in living animals. The activity of these antibiotics may be improved when used in combination with one or more of maltose, maltotriose, maltotetraose, maltopentaose, maltohexaose and maltoheptaose.